London, United Kingdom

Naseem Amin

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Naseem Amin: Innovator in Pharmaceutical Chemistry

Introduction

Naseem Amin is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on triethylenetetramine tetrahydrochloride. With a total of 5 patents to his name, Amin continues to push the boundaries of medical science.

Latest Patents

One of Naseem Amin's latest patents is focused on a new crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use. This invention describes a crystalline form that exhibits improved room temperature stability compared to known forms and the dichloride salt. The new crystalline form is characterized by specific peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6, and 35.3±0.1° 2θ, along with Raman shifts of 943, 1173, 1527, and 1612±5 cm. This innovative form is particularly useful in the treatment of Wilson's disease.

Career Highlights

Naseem Amin is currently associated with Orphalan S.A., where he continues to develop groundbreaking pharmaceutical solutions. His work has garnered attention in the scientific community, contributing to advancements in treatment options for various diseases.

Collaborations

Amin collaborates with notable colleagues, including Timothy James Morley and Ronnie Maxwell Lawrence. Their combined expertise enhances the innovative potential of their projects.

Conclusion

Naseem Amin stands out as a significant figure in pharmaceutical innovation, with his work on triethylenetetramine tetrahydrochloride paving the way for improved treatments. His contributions reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…